Dexmedetomidine in Splanchnic Nerve Neurolysis

• Status: Recruiting
• Trial end date: 2022-05-30
• Target enrollment: 0
• Participant gender: All

Summary

Malignancy related abdominal and pelvic pain can be debilitating and affects survival as well as quality of life. Pain from cancer and its treatments can result in anxiety, depression, fear, anger, helplessness, and hopelessness, and those with both pain and depression have an amplification of disability and poor quality of life Pancreatic and other upper abdominal organ malignancies can produce intense visceral pain syndromes that are frequently treated with splanchnic nerve neurolysis (SNN) or celiac plexus neurolysis (CPN). Dexmedetomidine is a selective alpha two adreno-receptor agonist. It provides dose-dependent sedation, analgesia, sympatholysis, and anxiolysis without relevant respiratory depression. Dexmedetomidine is used as adjuvant to LA drugs in peripheral nerve block, brachial plexus block and intrathecal anesthesia with satisfactory results. The aim of this study is to evaluate effect of addition of dexmedetomidine as an adjuvant to alcohol and local anesthetics for chemical neurolysis to control pain in patients with intra-abdominal malignancy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Minia University
• Treatments: Dexmedetomidine; Ethanol

Criteria

Inclusion Criteria:

• Patient diagnosed to have abdominal malignancy aged 25 to 70 years old

• Fully conscious

• Patient has no hematological disease or coagulation abnormality.

• Patient has no history of mental illness

• Patient with persistent and moderate to severe abdominal pain visual analogue scale score > 4.

Exclusion Criteria:

• Patient refusal of the procedure

• Extremes of age

• Patients with psychiatric disorders

• Patient diagnosed to have any coagulation defect or bleeding tendency

• Patients with cardiopulmonary significant condition

• Skin infection or wounds at site of proposed needle insertion site